TALVEY DIN 02547392
Status: Marketed
Holder: JANSSEN INC
Health Canada record
| Active ingredient(s) | TALQUETAMAB 2 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01FX29 TALQUETAMAB |
|---|
| Original market date | 04-Mar-2025 |
|---|
| Current status date | 04-Mar-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TALQUETAMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02547406 | TALVEY | JANSSEN INC | Solution | TALQUETAMAB 40 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 33154 | 2024-04-30 | New Drug Submission (NDS) | |
Request a quote for TALVEY
How to read a Canadian DIN record